化疗对乳腺癌患者外周血CD4^+CD25^+CD127^-调节性T细胞的影响被引量：1

Impact of chemotherapy on peripheral blood CD4^+CD25^+CD127^- regulatory T cells in breast cancer patients

导出

摘要目的观察化疗对乳腺癌患者外周血免疫指标的变化并探讨其影响。方法采用流式细胞术分析129例乳腺癌患者化疗前后CD4+CD25+CD127-调节性T细胞占CD4+T细胞的比率及T淋巴细胞亚群CD3、CD4、CD8;B淋巴细胞CD19;NK细胞(CD16+CD56)和CD4/CD8比值的动态变化。结果化疗后的乳腺癌患者CD4+CD25+CD127-调节性T细胞占CD4+细胞比率较化疗前降低,T淋巴细胞亚群中CD3、CD4、CD4/CD8增高,CD8、NK和CD19降低;乳腺癌患者外周血调节性T细胞的数量与临床分期和组织分化程度相关。结论乳腺癌患者化疗后调节性T细胞的数量降低,免疫调节抑制功能下降,免疫功能得到提高,但体液免疫及NK功能未见提高。 Objective To investigate the impact of chemotherapy on CD4＋CD25＋CD127-T regulatory cells in breast cancer patients.Methods We analyzed the peripheral blood cells,including NK,B lymphocyte CD19,and the T lymphocyte subgroups of CD3,CD4,CD8 and CD4＋CD25＋CD127-regulatory T cells in l29 patients with cancer before and after chemotherapy by flow cytometry.The ratio of CD4/CD8 was dynamically observed during the treatment.Results The cell counts of CD4,CD3 and the ratio of CD4/CD8 increased while the cell counts of CD8,NK,CD19 and the ratio of CD4＋CD25＋ CD127-regulatory T cells CD4＋ decreased after chemotherapy among breast cancer patients（P0.05）.The change of regulatory T cell numbers was associated with the clinical status of patients and the differentiation levels of cancer cells.Conclusion The function of immune modulation decreased during chemotherapy in the patients of breast cancer.

作者樊静任红张凤春景晓春李建柱康文喜

机构地区秦皇岛市肿瘤医院

出处《中国预防医学杂志》 CAS 2011年第10期881-883,共3页 Chinese Preventive Medicine

关键词乳腺癌化疗 CD4+CD25+CD127-调节性T细胞流式细胞术 Breast cancer CD4＋CD25＋CD127＋ regulatory T cell Flow cytometry

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献12

1Stephens LA, Barclay AN, Mason D. Phenotyp ic characteriza- tion of regulatory CD446+ CD25^+ T cells in rats [J].Int Imm- unol, 2004, 16 (2): 365 -375.
2Liu, VC, Wong LY, Jang, T, et al. Tumor Evasion of the Immune System by Converting CD4^+ CD25^+ T Cells into CD4^+ CD25^+ T Regulatory Cells: Role of Tumor- Derived TGF [J]. The Journal of Immunol gey, 2007, 178, 178: 2883- 2892.
3Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleis- chhauer K, Levings MK, lnterleukin 10 secreting type 1 reg- ulatory T cells in rodents and humans [J].Immunol Rev 2006, 212.212:28- 50.
4Liu CH, Chang SH, Narko K, et al. Overexpression of cy clooxygenase 2 is sufficient to induce tumorigenesis in trans genic mice [J].Biol. Chem, 2001, 276 276: 18563- 18569.
5Coombes JL, Siddiqui KR, Arancibia Cdrcamo CV, et al. A functionally specialized population of mucosal CD103^+ DCs in- ducts Foxp3+ regulatory T cells via a TGF and retinoic acid dependent mechanism [J]. Exp Med, 2007, 204 204: 1757 -1764.
6Hori S, Nomura T &. Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3 [J]. Science, 2003, 299 299:1057 -1061.
7Valzasina B, Piconese S, Guiducci C, et al. Tumor induced ex- pansion of regulatory T cells by conversion of CD4^+ CD25 lym- phocytes is thymus and proliferation independent [J]. Cancer Res, 2006, 66 66:4488 -4495.
8刘莉,丁乾,曹如波,王晶,姚军霞,黄士昂.恶性肿瘤患者外周血CD4^+ CD25^+调节T细胞的检测及其临床意义[J].临床肿瘤学杂志,2005,10(4):342-345. 被引量：16
9Liyanage UK, Moore TT, Joo HG, et al. Prevalence of egu- latory T cells is increased in peripheral blood and tumormicro 2 envionment of patients with 33 pancreasor breast adenocarcino- ma [J] . Immunol, 2002, 169 (2): 756-2 761.
10Sasada T, Kimura M, Yoshida Y, et al. CD4^+ CD25^+ regula- tory T cells in patients with gastrointestinalmalignancies: pos- sible involvement of regulatory T cells, in disease p rogression [J].Cancer, 2003, 98 (5) : 1089- 1099.

二级参考文献8

1Itoh M, Takahashi T, Sakaguchi, et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance[J]. J Immunol,1999,162(9):5317-5326.
2Seo N, Hayakawa S, Takigawa M, et al. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity[J]. Immunology, 2001,103(4):449-457.
3Rosenberg SA. Progress in human tumour immunology and immunotherapy[J]. Nature, 2001,411:380-384.
4Seitz J, Bruck J, Lenz J, et al. Deletion of CD4+ CD25+ T cells and treatment with tyrosinase-related protein2-transduced dendritic cells enhance the interferon alpha-induced, CD8+ T-cell-dependent immune defense of B16 melonoma[J]. Cancer Res, 2001,61:8643-8646.
5Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses[J]. J Exp Med,2001,194(6):823-832.
6Tanaka H, Tanaka J, Kjaergaard J, et al. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes[J]. J Immunother,2002,25(3):207-217.
7Wolf AM, Wolf D, Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients[J]. Clin Cancer Res,2003,9(2):606-612.
8Sasada T, Kimura M, Yoshida Y, et al. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression[J]. Cancer, 2003,98(5):1089-1099.